Barry Freedman to Disease Progression
This is a "connection" page, showing publications Barry Freedman has written about Disease Progression.
Connection Strength
2.586
-
Wagenknecht LE, Divers J, Register TC, Russell GB, Bowden DW, Xu J, Langefeld CD, Lenchik L, Hruska KA, Carr JJ, Freedman BI. Bone Mineral Density and Progression of Subclinical Atherosclerosis in African-Americans With Type 2 Diabetes. J Clin Endocrinol Metab. 2016 11; 101(11):4135-4141.
Score: 0.489
-
Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014 Feb; 66(2):390-6.
Score: 0.410
-
Freedman BI, Spainhour M, Hicks PJ, Turner J, Robertson J, Langefeld CD, Murea M, Divers J. Nephropathy Progression in African Americans With a Family History of ESKD: Implications for Clinical Trials in APOL1-Associated Nephropathy. Am J Kidney Dis. 2019 08; 74(2):284-286.
Score: 0.147
-
Ma L, Divers J, Freedman BI. Mechanisms of Injury in APOL1-associated Kidney Disease. Transplantation. 2019 03; 103(3):487-492.
Score: 0.146
-
Langefeld CD, Comeau ME, Ng MCY, Guan M, Dimitrov L, Mudgal P, Spainhour MH, Julian BA, Edberg JC, Croker JA, Divers J, Hicks PJ, Bowden DW, Chan GC, Ma L, Palmer ND, Kimberly RP, Freedman BI. Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions. Kidney Int. 2018 09; 94(3):599-607.
Score: 0.138
-
Parsa A, Kanetsky PA, Xiao R, Gupta J, Mitra N, Limou S, Xie D, Xu H, Anderson AH, Ojo A, Kusek JW, Lora CM, Hamm LL, He J, Sandholm N, Jeff J, Raj DE, Böger CA, Bottinger E, Salimi S, Parekh RS, Adler SG, Langefeld CD, Bowden DW, Groop PH, Forsblom C, Freedman BI, Lipkowitz M, Fox CS, Winkler CA, Feldman HI. Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study. J Am Soc Nephrol. 2017 Mar; 28(3):923-934.
Score: 0.123
-
Freedman BI. APOL1 and kidney disease: new insights leading to novel therapies. Am J Kidney Dis. 2015 Jul; 66(1):9-11.
Score: 0.113
-
Freedman BI, Skorecki K. Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy. Clin J Am Soc Nephrol. 2014 Nov 07; 9(11):2006-13.
Score: 0.105
-
Freedman BI. APOL1 and nephropathy progression in populations of African ancestry. Semin Nephrol. 2013 Sep; 33(5):425-32.
Score: 0.099
-
Hicks PJ, Langefeld CD, Lu L, Bleyer AJ, Divers J, Nachman PH, Derebail VK, Bowden DW, Freedman BI. Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans. Kidney Int. 2011 Dec; 80(12):1339-43.
Score: 0.086
-
Freedman BI, Sedor JR. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 12 23; 363(26):2565; author reply 2565-6.
Score: 0.083
-
Murea M, Freedman BI. Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens. 2010 May; 19(3):235-41.
Score: 0.079
-
Bostrom MA, Freedman BI. The spectrum of MYH9-associated nephropathy. Clin J Am Soc Nephrol. 2010 Jun; 5(6):1107-13.
Score: 0.078
-
Reeves-Daniel AM, Iskandar SS, Bowden DW, Bostrom MA, Hicks PJ, Comeau ME, Langefeld CD, Freedman BI. Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report. Am J Kidney Dis. 2010 May; 55(5):e21-4.
Score: 0.078
-
Liu Y, Freedman BI. Genetics of progressive renal failure in diabetic kidney disease. Kidney Int Suppl. 2005 Dec; (99):S94-7.
Score: 0.058
-
Satko SG, Freedman BI. The familial clustering of renal disease and related phenotypes. Med Clin North Am. 2005 May; 89(3):447-56.
Score: 0.056
-
Malhotra R, Katz R, Jotwani V, Ambrosius WT, Raphael KL, Haley W, Rastogi A, Cheung AK, Freedman BI, Punzi H, Rocco MV, Ix JH, Shlipak MG. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD. Clin J Am Soc Nephrol. 2020 03 06; 15(3):349-358.
Score: 0.039
-
Young BA, Blacksher E, Cavanaugh KL, Freedman BI, Fullerton SM, Kopp JB, Umeukeje EM, West KM, Wilson JG, Burke W. Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions. Am J Nephrol. 2019; 50(4):303-311.
Score: 0.038
-
Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene T. Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. J Am Soc Nephrol. 2019 08; 30(8):1523-1533.
Score: 0.037
-
Jotwani VK, Lee AK, Estrella MM, Katz R, Garimella PS, Malhotra R, Rifkin DE, Ambrosius W, Freedman BI, Cheung AK, Raphael KL, Drawz P, Neyra JA, Oparil S, Punzi H, Shlipak MG, Ix JH. Urinary Biomarkers of Tubular Damage Are Associated with Mortality but Not Cardiovascular Risk among Systolic Blood Pressure Intervention Trial Participants with Chronic Kidney Disease. Am J Nephrol. 2019; 49(5):346-355.
Score: 0.037
-
Hawkins GA, Friedman DJ, Lu L, McWilliams DR, Chou JW, Sajuthi S, Divers J, Parekh RS, Li M, Genovese G, Pollack MR, Hicks PJ, Bowden DW, Ma L, Freedman BI, Langefeld CD. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression. Am J Nephrol. 2015; 42(2):99-106.
Score: 0.029
-
Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013 Dec 05; 369(23):2183-96.
Score: 0.025
-
Chen Y, Lipkowitz MS, Salem RM, Fung MM, Bhatnagar V, Mahata M, Nievergelt CM, Rao F, Mahata SK, Schork NJ, Hicks PJ, Bowden DW, Freedman BI, Brophy VH, O'Connor DT. Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. Am J Nephrol. 2010; 32(1):23-30.
Score: 0.020
-
Bleyer AJ, Sedor JR, Freedman BI, O'Brien A, Russell GB, Graley J, Schelling JR. Risk factors for development and progression of diabetic kidney disease and treatment patterns among diabetic siblings of patients with diabetic kidney disease. Am J Kidney Dis. 2008 Jan; 51(1):29-37.
Score: 0.017
-
Leon JM, Freedman BI, Miller MB, North KE, Hunt SC, Eckfeldt JH, Lewis CE, Kraja AT, Djoussé L, Arnett DK. Genome scan of glomerular filtration rate and albuminuria: the HyperGEN study. Nephrol Dial Transplant. 2007 Mar; 22(3):763-71.
Score: 0.016
-
Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW. Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS). Am Heart J. 2006 Mar; 151(3):706-11.
Score: 0.015
-
Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, Clark RA, Anderson SA, O'connell RJ, Agan BK, Ahuja SS, Bologna R, Sen L, Dolan MJ, Ahuja SK. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005 Mar 04; 307(5714):1434-40.
Score: 0.014
-
Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2004 Jan-Feb; 24(1):32-40.
Score: 0.013